A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy.

摘要: Cancer scientists and clinicians are mourning the death of one most accomplished members their community: Dr. John Mendelsohn. He was a pioneer in targeted cancer therapy instrumental for discovery deployment first antagonist epidermal growth factor receptor (EGFR) therapeutic antibodies, broadening concept EGFR to encompass other tyrosine kinases, such as HER2, developing blocking antibody-combination with chemotherapies or radiotherapy. Mendelsohn, who died on January 7, 2019, always led by strength his accomplishments humility character. Above all, he well-revered mentor clinician, extended compassion gift time patients, colleagues, mentees alike. In tribute Research has invited former colleagues were associated Mendelsohn over three decades reflect broad impact work. Here, we discuss Mendelsohn's illustrious career at elite academic institutions hospitals United States, acumen build, grow, uplift institutions, train generation medical oncologists, physician scientists, biologists. His profound legacy research treatment continue prolong save lives patients globally.